As of close of business last night, Novo Nordisk A/S’s stock clocked out at $162.44, up 0.41% from its previous closing price of $161.78. In other words, the price has increased by $+0.66 from its previous closing price. On the day, 1556551 shares were traded. NVO stock price reached its highest trading level at $162.75 during the session, while it also had its lowest trading level at $160.95.
Unlock the Hottest Top 10 Penny Stocks Today! Discover Now
Dive into the world of lucrative penny stocks with MarketClub's groundbreaking "Smart Scan" technology! Get an instant snapshot of the top 50 high volume stocks with a clear direction and outstanding liquidity - in other words, the strongest trending. To unlock this exclusive list, simply provide your first name, last name, and email for instant access.
Gain Access to Top 10 Penny Stocks Now!.
To gain a deeper understanding of NVO’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 0.70 and its Current Ratio is at 0.90. In the meantime, Its Debt-to-Equity ratio is 0.32 whereas as Long-Term Debt/Eq ratio is at 0.30.
Upgrades & Downgrades
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, NVO now has a Market Capitalization of 359.85B and an Enterprise Value of 359.52B. As of this moment, Novo’s Price-to-Earnings (P/E) ratio for their current fiscal year is 41.78, and their Forward P/E ratio for the next fiscal year is 28.60. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 14.92. For the stock, the TTM Price-to-Sale (P/S) ratio is 10.08 while its Price-to-Book (P/B) ratio in mrq is 31.60. Its current Enterprise Value per Revenue stands at 1.91 whereas that against EBITDA is 4.31.
Stock Price History:
Over the past 52 weeks, NVO has reached a high of $172.97, while it has fallen to a 52-week low of $95.02. The 50-Day Moving Average of the stock is 162.20, while the 200-Day Moving Average is calculated to be 131.70.
It appears that NVO traded 1.43M shares on average per day over the past three months and 1.45M shares per day over the past ten days. A total of 2.25B shares are outstanding, with a floating share count of 1.18B. Insiders hold about 26.40% of the company’s shares, while institutions hold 8.40% stake in the company. Shares short for NVO as of Apr 27, 2023 were 1.47M with a Short Ratio of 1.56M, compared to 2.33M on Mar 30, 2023.
Dividends & Splits
With its trailing 12-month dividend rate of 0.00, NVO has a forward annual dividend rate of 1.76. Against a Trailing Annual Dividend Yield of 0.00%, it implies a Forward Annual Dividend Yield of 1.03%. The stock’s 5-year Average Dividend Yield is 1.93. The current Payout Ratio is 33.02% for NVO, which recently paid a dividend on Apr 03, 2023 with an ex-dividend date of Mar 23, 2023. Stock splits for the company last occurred on Jan 08, 2014 when the company split stock in a 5:1 ratio.
As of right now, 2 analysts gave their recommendation on the stock of the company. On average, analysts expect EPS of $1.23 for the current quarter, with a high estimate of $1.28 and a low estimate of $1.19, while EPS last year was $0.78. The consensus estimate for the next quarter is $1.32, with high estimates of $1.37 and low estimates of $1.27.
Analysts are recommending an EPS of between $5.27 and $4.81 for the fiscal current year, implying an average EPS of $5. EPS for the following year is $5.67, with 3 analysts recommending between $6.27 and $5.31.
In the current quarter, 1 analysts expect revenue to total $7.99B. It ranges from a high estimate of $7.99B to a low estimate of $7.99B. As of the current estimate, Novo Nordisk A/S’s year-ago sales were $5.65B, an estimated increase of 41.40% from the year-ago figure. For the next quarter, 1 analysts are estimating revenue of $8.45B, an increase of 29.50% less than the figure of $41.40% in the same quarter last year. There is a high estimate of $8.45B for the next quarter, whereas the lowest estimate is $8.45B.
A total of 3 analysts have provided revenue estimates for NVO’s current fiscal year. The highest revenue estimate was $33.31B, while the lowest revenue estimate was $31.03B, resulting in an average revenue estimate of $31.83B. In the same quarter a year ago, actual revenue was $25.66B, up 24.00% from the average estimate. Based on 3 analysts’ estimates, the company’s revenue will be $36.88B in the next fiscal year. The high estimate is $40.48B and the low estimate is $34.99B. The average revenue growth estimate for next year is up 15.80% from the average revenue estimate for this year.